Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018

Sci Rep. 2022 Aug 3;12(1):13332. doi: 10.1038/s41598-022-17600-6.

Abstract

Streptococcus pneumoniae continues to cause significant disease burden. Whilst pneumococcal conjugate vaccines (PCV) have substantially reduced this burden, serotype replacement partially negates this success due to increased disease associated with non-vaccine serotypes (NVTs). Continued surveillance is therefore essential to provide crucial epidemiological data. Annual cross-sectional surveillance of paediatric pneumococcal carriage was started in Southampton, UK following PCV7 roll-out in 2006. Nasopharyngeal swabs were collected from children < 5 years old each winter (October to March) from 2006/07 and for each consecutive year until 2017/18. Pneumococcal serotype was inferred from whole genome sequencing data. A total of 1429 (32.5%) pneumococci were isolated from 4093 children. Carriage ranged from 27.8% (95%CI 23.7-32.7) in 2008/09 to 37.9% (95%CI 32.8-43.2) in 2014/15. Analyses showed that carriage increased in children aged 24-35 months (p < 0.001) and 47-60 months (p < 0.05). Carriage of PCV serotypes decreased markedly following PCV7 and/or PCV13 introduction, apart from serotype 3 where the relative frequency was slightly lower post-PCV13 (pre-PCV13 n = 7, 1.67%; post-PCV13 n = 13, 1.27%). Prevalence of NVTs implicated in increased disease was low with 24F (n = 19, 1.4%) being the most common followed by 9N (n = 11, 0.8%), 8 (n = 7, 0.5%) and 12F (n = 3, 0.2%).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carrier State / epidemiology
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Humans
  • Infant
  • Nasopharynx
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines
  • Prevalence
  • Serogroup
  • Streptococcus pneumoniae* / genetics
  • United Kingdom / epidemiology
  • Vaccines, Conjugate

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate